Related Experiment Video

Updated: Jun 10, 2026

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis
03:23

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Published on: May 10, 2024

Reslizumab for pediatric eosinophilic esophagitis

Garry M Walsh1

  • 1School of Medicine & Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK. g.m.walsh@abdn.ac.uk

Immunotherapy
|July 20, 2010
PubMed

Insights

Pediatric eosinophilic esophagitis involves eosinophil buildup in the esophagus. Reslizumab, an IL-5 antibody, is being developed to treat this condition by targeting eosinophil accumulation.

Area of Science:

  • Immunology
  • Gastroenterology
  • Pediatrics

Background:

  • Pediatric eosinophilic esophagitis is a chronic inflammatory disorder characterized by eosinophil infiltration in the esophageal mucosa.
  • Eosinophils are key inflammatory cells implicated in various allergic conditions affecting the respiratory and gastrointestinal tracts.
  • Interleukin-5 (IL-5) plays a critical role in eosinophil development, survival, and tissue accumulation.

Purpose of the Study:

  • To review the clinical development status of reslizumab for treating pediatric eosinophilic esophagitis.
  • To highlight reslizumab's mechanism of action as an IL-5 inhibitor.

Main Methods:

  • Review of clinical trial data and scientific literature on reslizumab.
  • Focus on reslizumab's efficacy and safety in pediatric populations.

Main Results:

  • Reslizumab is a humanized monoclonal antibody targeting IL-5.
  • It demonstrates potent IL-5 neutralizing capabilities.
  • Potential therapeutic agent for eosinophilic diseases, including pediatric eosinophilic esophagitis.

Conclusions:

  • Reslizumab shows promise as a targeted therapy for pediatric eosinophilic esophagitis.
  • Further clinical development is ongoing to establish its role in managing this condition.
  • Targeting IL-5 offers a specific approach to reduce eosinophilic inflammation.

More Related Videos

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation10:15

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.